Supplementary Tables 1 - 3, Figures 1 - 7 from An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

PDF file - 166K, Supplementary Table S1: TF HuMab: target binding characteristics and inhibition of FXa generation. Supplementary Table S2: Cross-competition between TF HuMab. Supplementary Table S3: Thromboelastography: coagulation of LPS-stimulated whole blood in the presence of 20 microg/mL TF-011, TF-013 or TF-098. Supplementary Figure S1: TF HuMab inhibit TF:FVIIa-induced ERK1/2 phosphorylation. Supplementary Figure S2: TF:FVIIa-induced IL-8 production in MDA-MB-231 cells is reduced in the presence of TF HuMab. Supplementary Figure S3: Binding of TF HuMab is unaltered after conjugation with vcMMAE or mcMMAF. Supplementary Figure S4: Anti-tumor activity of TF-ADCs in the A431 and HCT-116 xenograft models. Supplementary Figure S5: Anti-tumor activity of unconjugated TF HuMab in vivo. Supplementary Figure S6: Post-paclitaxel treatment with TF-011-MMAE in PDX models. Supplementary Figure S7: Full-length blots for Figure 1C.